Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.54 |
| ▸ | RELA | Q04206 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24961123 | 0.84 | ALDH1A1 (0.58) | ALDH1A1L3MBTL1LMNAALOX15TSHR | |
| SCHEMBL18649489 | 0.83 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1LMNAALOX15TSHR | |
| SCHEMBL569032 | 0.80 | ALDH1A1 (0.67) | ALDH1A1L3MBTL1LMNAALOX15TSHR | |
| SCHEMBL193533 | 0.80 | ALDH1A1 (0.62) | ALDH1A1L3MBTL1LMNAALOX15TSHR | |
| SCHEMBL6319718 | 0.80 | ALDH1A1 (0.66) | ALDH1A1L3MBTL1LMNAALOX15TSHR | |
| SCHEMBL6275655 | 0.79 | ALDH1A1 (1.00) | ALDH1A1L3MBTL1LMNAALOX15TSHR | |
| SCHEMBL24960936 | 0.79 | DYRK1A (0.52) | ALDH1A1L3MBTL1LMNARAB9ANPC1 | |
| SCHEMBL2170056 | 0.78 | ALDH1A1 (0.64) | ALDH1A1L3MBTL1LMNAALOX15TSHR | |
| SCHEMBL836745 | 0.78 | SMN1; SMN2 (0.65) | ALDH1A1L3MBTL1LMNAALOX15TSHR | |
| SCHEMBL28727291 | 0.78 | SMN1; SMN2 (0.65) | ALDH1A1L3MBTL1LMNAALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-11760722-B2 | Inhibitors of cysteine proteases and methods of use thereof | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-09-19 | — | — | US | disclosed |
| US-11753373-B2 | Protease inhibitors as antivirals | ACEA Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753373-B2 | Protease inhibitors as antivirals | ACEA Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230234921-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234921-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230159451-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159451-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-11225505-B2 | Antimicrobial polymyxin derivative compounds | MONASH UNIVERSITY (AU) | 2022-01-18 | — | — | US | disclosed |
| US-7825152-B2 | serine protease inhibitors, for the treatment of hepatitis c virus infections | NOVARTIS AG (CH) | 2010-11-02 | — | — | US | disclosed |
| US-20100173851-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2010-07-08 | — | — | US | disclosed |
| US-20100173851-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2010-07-08 | — | — | US | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| US-20070292933-A1 | Inhibitors of serine proteases, particular HCV NS3-NS4A protease | PITLIK JANOS | 2007-12-20 | — | — | US | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070265281-A1 | Organic Compounds and Their Uses | COTTENS SYLVAIN | 2007-11-15 | — | — | US | disclosed |
| US-7273885-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234921-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | SERPINB1, CTSV, CTSE | ALDH1A1 2826/4885L3MBTL1 1893/4885LMNA 2364/4885 |
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | TRIM33, TRIM28, TRIM4 | ALDH1A1 3246/4885L3MBTL1 487/4885LMNA 1670/4885 |
| US-20070292933-A1 | Inhibitors of serine proteases, particular HCV NS3-NS4A protease | SERPINB1, PRSS1, SPINT2 | ALDH1A1 2044/4885L3MBTL1 1699/4885LMNA 1649/4885 |
| US-11225505-B2 | Antimicrobial polymyxin derivative compounds | VIP, PNKP, PEPD | ALDH1A1 4859/4885L3MBTL1 1643/4885LMNA 3070/4885 |
| US-20070286842-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | ALDH1A1 135/4885L3MBTL1 688/4885LMNA 1174/4885 |
| US-20100173851-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | SERPINB1, PRSS1, SPINT2 | ALDH1A1 2015/4885L3MBTL1 1764/4885LMNA 1651/4885 |
| US-20080045530-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | ALDH1A1 135/4885L3MBTL1 688/4885LMNA 1174/4885 |
| US-11753373-B2 | Protease inhibitors as antivirals | ACE, ACE2, TMPRSS15 | ALDH1A1 3270/4885L3MBTL1 1099/4885LMNA 1247/4885 |
| US-20070265281-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | ALDH1A1 135/4885L3MBTL1 688/4885LMNA 1174/4885 |
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACE, ACE2, TMPRSS15 | ALDH1A1 3270/4885L3MBTL1 1099/4885LMNA 1247/4885 |
| US-20230159451-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | SERPINB1, CTSV, CTSE | ALDH1A1 2826/4885L3MBTL1 1893/4885LMNA 2364/4885 |
| US-11760722-B2 | Inhibitors of cysteine proteases and methods of use thereof | SERPINB1, PREP, DNPEP | ALDH1A1 1556/4885L3MBTL1 2310/4885LMNA 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.